Predicting smell recovery in patients with nasal polyps treated with dupilumab
Official title: Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Run by Northwestern University · NCT06892704 · Data updated 2026-11-12
This study is trying to see if certain factors can help predict how well people with nasal polyps will recover their sense of smell after being treated with dupilumab.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Northwestern University Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | April 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT06892704 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a well-documented history of chronic rhinosinusitis with nasal polyps and a stable olfactory deficit lasting more than three months.
✕Probably not a fit
Patients who do not have chronic rhinosinusitis with nasal polyps or have not experienced a stable olfactory deficit may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify predictors for the restoration of the sense of smell in patients suffering from chronic rhinosinusitis with nasal polyps who are being treated with dupilumab. It will assess the degree of olfactory cleft obstruction and measure electrophysiological signals related to breathing and sniffing behavior. Participants will be monitored over a six-month period to evaluate changes in their olfactory function. The study seeks to understand the relationship between these factors and the potential recovery of smell.
Why it matters
Potential benefit: If successful, this study could help identify which patients are most likely to regain their sense of smell after treatment with dupilumab.
How similar studies have gone: While this approach is observational, similar studies have shown promise in understanding olfactory recovery in related conditions, though this specific predictive methodology may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Well documented history of CRSwNP * BSIT age/sex classified as "abnormal" score * Self-reported stable olfactory deficit of moderate to severe quality \> 3 months * Prior endoscopic sinus surgery \>3 months, \<10 years prior
Where it's running
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States Recruiting
Study contacts
- Study coordinator: Clinical Coordinator
- Email: aditi.agarwal@northwestern.edu
- Phone: 312 6958182
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dupilumab for Major Depressive Disorder
This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.
-
See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis
This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.
-
Smell training in CRS patients with smell loss
This study tests whether a 3-month smell training program can improve smell function and related immune and mental health measures in adults with chronic rhinosinusitis and smell loss.
-
Dupilumab in COPD: Real-world Registry of Outcomes
This registry tests how dupilumab works for COPD patients in everyday care and whether it lowers flare-ups and improves lung function and quality of life.
-
Dupilumab added to standard COPD care after a flare-up
This study tests whether adding dupilumab to usual COPD care after a severe flare requiring hospitalization can reduce the chance of another flare.
-
Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis
This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.